This website is intended for healthcare professionals only

touchCARDIO

Search

Cardiovascular Disease

Peter Toth shares his highlights from the ASPC 2022 Congress on CVD Prevention!

3 mins

Published Online: Aug 25th 2022

Dr Peter Toth (President of the American Society for Preventive Cardiology [ASPC]) shares his highlights from the 2022 Congress on CVD Prevention. Find out more about the importance of the A, B, Cs of preventive cardiology and personalized patient care.

Questions

What were your highlights of the ASPC 2022 Congress on CVD Prevention? (00:15-00:52)
2. Please summarize some of the most exciting data presented and hottest topics this year? (00:52-03:14)

Disclosures: Peter Toth is a consultant for Kowa, Merck, Novartis and Resverlogix, and is a Speaker’s Bureau participant with Amgen, Esperion and Novo-Nordisk.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the ASPC 2022 Congress on CVD Prevention

Trending Topic

Developed by Touch

EuroPCR 2026: Selected late-breaking trials from Day 3

New late-breaking data presented on Day 3 of EuroPCR 2026 highlighted evolving approaches to antiplatelet therapy, transcatheter treatment of pure aortic regurgitation and procedural optimization in bicuspid TAVR

Related Videos in Cardiovascular Disease

Developed by Touch

BIO LIBRA: ICD versus CRTD in Non-ischaemic Cardiomyopathy Outcomes by Sex

Valentina Kutyifa

In this interview, Dr Valentina Kutyifa, University of Rochester Medical Center, Rochester, NY, USA, offers insight into the BIO LIBRA study (ClinicalTrials.gov identifier: NCT03884608), a landmark trial designed to reassess outcomes in patients with non-ischaemic cardiomyopathy in the era of contemporary medical therapy. Recognizing that much of the original evidence supporting implantable cardioverter-defibrillator (ICD) use in this population dates back decades, the BIO LIBRA study was initiated to fill key knowledge gaps using modern treatment protocols.

Developed by Touch

PRAETORIAN XL: Long-Term Outcomes of Subcutaneous versus Transvenous ICD Therapy

Louise Olde Nordkamp

In this interview, Dr Louise Olde Nordkamp, a device cardiologist at Amsterdam University Medical Center, discusses the long-term findings of the PRAETORIAN XL trial—a follow-up study comparing transvenous and subcutaneous implantable cardioverter-defibrillators (ICDs). Building on the original PRAETORIAN trial, this extended 8-year analysis evaluated device-related complications and confirmed that subcutaneous ICDs carry fewer major and lead-related complications. Dr Olde Nordkamp highlights the clinical relevance of these results, supporting broader consideration of subcutaneous ICDs in patients without pacing indications.

Developed by Touch

2025 Updates to the Guidelines for the Management of Acute Coronary Syndromes

Sunil Rao

Acute coronary syndromes (ACS) take center stage in this timely interview with Professor Sunil Rao of NYU Grossman School of Medicine and NYU Langone Health System, New York, NY, USA, as he delves into the driving forces behind the much-anticipated 2025 updates to the ACS management guidelines presented at ACC.25, Chicago, IL, USA, 29–31 March 2025.

Developed by Touch

Artificial intelligence enabled obstetric cardiovascular screening in SPEC-AI Nigeria

Demilade Adedinsewo

touchCARDIO coverage of data presented at ESC 2024 touchCARDIO spoke with Dr Demilade Adedinsewo, non-invasive cardiologist at Mayo Clinic, Jacksonville, FL, USA to discuss artificial intelligence-enabled obstetric cardiovascular screening in the SPEC-AI Nigeria randomized clinical trial (ClinicalTrials.gov identifier: NCT05438576). The ...

Developed by Touch

Alipoprotein A-I infusions and cardiovascular outcomes

Charles Michael Gibson

touchCARDIO spoke with Dr Mike Gibson, Harvard Medical School, Boston, MA, USA to discuss the results of his trial investigating the relationship between apolipoprotein A-I infusions and cardiovascular outcomes, presented at ESC 2024. He explains that while high-density lipoprotein (HDL) is generally associated with good outcomes, not all HDL is equally effective at removing cholesterol from plaque, a process known as cholesterol efflux, which is crucial for better outcomes after a heart attack.

Developed by Touch

John Forrest, ACC 2023: Evolut low risk trial, transcatheter versus surgical aortic valve replacement in patients at low surgical risk

The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New ...

Developed by Touch

John Forrest, ACC 2023: The treatment paradigm for patients with aortic stenosis

The treatment paradigm for aortic stenosis has developed dramatically in the past decade. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to outline and discuss the developments. Dr ...

Developed by Touch

Steven Nissen, ACC 2023: Lipid-lowering therapies - current and future options

Many lipid-lowering therapies exist, such as statins to manage and reduce lipid levels. While statins are the most commonly used medication, some patients may need additional interventions to lower their LDL cholesterol levels. In this touchCARDIO interview, we speak with ...

Developed by Touch

Steven Nissen, ACC 2023: CLEAR OUTCOMES trial - Bempedoic acid and cardiovascular outcomes in statin intolerant patients

CLEAR OUTCOMES trial investigated bempedoic acid and cardiovascular outcomes in statin intolerant patients with high cardiovascular risk. Prof. Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) addresses the findings, and what the implications are for clinical practice and patient care in ...

Developed by Touch

Annapoorna Kini, ACC 2023: Evolocumab in patients with stable coronary artery disease, the Yellow III study

The Yellow III study aimed to assess the effect of evolocumab in combination with statins on plaque morphology in patients with stable coronary artery disease. In this touchCARDIO interview, we speak with Dr Annapoorna Kini (Cardiac Catheterization Laboratory, Mount Sinai ...

Developed by Touch

Annapoorna Kini, ACC 2023: PCSK9 inhibitors for acute coronary syndrome

Evolocumab is a proprotein convertase subtilisin kexin type 9 inhibitor (PCSK9 inhibitor). When used in combination with statins, reduced plaque volume has been observed in patients with acute coronary syndrome (ACS). In this touchCARDIO interview, we speak with Dr Annapoorna Kini (...

Developed by Touch

Divaka Perera, ACC 2023: Myocardial viability in patients with ischaemic left ventricular dysfunction, the REVIVED-BCIS2 trial

The REVIVED-BCIS2 trial assessed the use of myocardial viability tests in predicting prognosis following revascularization in patients with ischaemic left ventricular dysfunction. In this touchCARDIO interview, we speak with Professor Divaka Perera (Guy's and St Thomas' NHS Foundation Trust, London, ...

Latest articles videos and clinical updates - straight to your inbox

Sign Up

Login

Sign Up FREE

Log into your Touch Account

Keep track of your clinical interests and newsletter subscriptions.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Sign up with an Email

Sign up with Google

Sign up with Facebook

Sign up with LinkedIn

Sign up with Microsoft

Already have an Account?

Login

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

Register now for FREE access

Already registered? Login below.

Register

Login